Norvatis Novel Bone Marrow Drug Successful in Meeting its Goal

Norvatis Novel Bone Marrow Drug Successful in Meeting its Goal

It has been revealed by Swiss drug maker that Novartis bone marrow cancer drug is successful in meeting its goal. It has been revealed that LBH589, bone marrow drug, when combined with bortezomib and dexamethasone shows significant results in survival of patient.

Multiple myeloma is a cancer that starts in plasma cells in bone marrow and hinders the production of normal blood cells. It has been reported that this cancer is caused in about 20% of every 100,000 people across the world every year. Researchers said that this cancer is mainly caused in those, who are above 50 years of age.

Norvatis claims that this drug has the capability to rank at the highest level in a new list of treatments for the incurable disease. Alessandro Riva, Novartis Global Head of Oncology, said that the LBH589 is declared as the important treatment option for multiple myeloma.

It has been revealed that this drug blocks a key cancer cell enzyme which stresses the cancerous cells and ultimately kills them. MorphoSys and Celgene are the two German Biotech companies that are also working on treatments for multiple myeloma.

The Novartis investigational compound LBH589 basically extends the time of progression free survival in Phase III multiple myeloma.

economie: 
entreprises: 
nouvelles generales: 
Share Share